NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 110 | Europe, Canada, US, RoW | Efgartigimod IV, Placebo IV | argenx | Generalized Myasthenia Gravis | 07/25 | 07/27 | | |
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 235 | Europe, Canada, Japan, US, RoW | Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918 | Regeneron Pharmaceuticals | Generalized Myasthenia Gravis | 05/25 | 03/28 | | |
